GU Symposium 2015

Renal Cell Cancer: Keynote Lecture From GU Symposium 2015

Renal Cell Cancer: Keynote Lecture From GU Symposium 2015

By

Toni K. Choueiri, MD, delivered a keynote lecture on recent advances in the treatment of renal cell carcinoma at the 2015 GU Symposium.

Body Mass Index Predicts Survival in Metastatic Clear Cell Renal Cell Carcinoma

Body Mass Index Predicts Survival in Metastatic Clear Cell Renal Cell Carcinoma

By

Body mass index (BMI) predicts survival and overall response rates in patients with metastatic clear cell renal cell carcinoma.

Proteomic Markers Might Predict Clear Cell Renal Cell Carcinoma Survival

Proteomic Markers Might Predict Clear Cell Renal Cell Carcinoma Survival

By

Protein expression markers predict disease-specific survival (DSS) in clear cell renal cell carcinoma (ccRCC).

Adjuvant Sorafenib, Sunitinib for Advanced Renal Cell Carcinoma 'Should Not Be Pursued'

Adjuvant Sorafenib, Sunitinib for Advanced Renal Cell Carcinoma 'Should Not Be Pursued'

By

Adjuvant sorafenib and sunitinib do not improve survival for patients with locally advanced renal cell carcinoma (RCC).

International Collaboration Studies Teratoma with Malignant Transformation's 'Dismal' Outcomes

International Collaboration Studies Teratoma with Malignant Transformation's 'Dismal' Outcomes

By

Optimal chemotherapy remains unclear for metastatic teratoma with malignant transformation (TMT).

MicroRNA miR-371a-3p Levels a Promising Biomarker in Testicular Germ Cell Tumors

MicroRNA miR-371a-3p Levels a Promising Biomarker in Testicular Germ Cell Tumors

By

Circulating microRNA miR-371a-3p levels appear to be a promising biomarker of tumor bulk in testicular germ cell tumors (GCTs).

Neutrophil to Lymphocyte Ratio Change Associated with Survival after Targeted Therapy for mRCC

Neutrophil to Lymphocyte Ratio Change Associated with Survival after Targeted Therapy for mRCC

By

Baseline and changed neutrophil to lymphocyte ratio predict targeted treatment responses in metastatic renal cell carcinoma (mRCC).

Adjuvant Chemotherapy Improves Survival in Advanced Nonmetastatic Bladder Cancer

Adjuvant Chemotherapy Improves Survival in Advanced Nonmetastatic Bladder Cancer

By

Adjuvant chemotherapy is associated with better survival among patients with advanced nonmetastatic bladder cancer.

Short-Term ADT Does Not Improve Radiotherapy-Associated Survival in Prostate Cancer

Short-Term ADT Does Not Improve Radiotherapy-Associated Survival in Prostate Cancer

By

Adding short-term androgen deprivation therapy to radiotherapy does not improve overall survival in intermediate-risk prostate cancer.

Dose-Escalated Radiotherapy Does Not Improve Survival in Localized Prostate Cancer

Dose-Escalated Radiotherapy Does Not Improve Survival in Localized Prostate Cancer

By

Dose-escalated radiotherapy does not improve overall survival compared with lower-dose radiotherapy regimens for localized prostate cancer.

Low-Dose Brachytherapy Improves Disease-Free Survival in Unfavorable-Risk Prostate Cancer

Low-Dose Brachytherapy Improves Disease-Free Survival in Unfavorable-Risk Prostate Cancer

By

Low-dose-rate brachytherapy boost (LDR-PB) achieves better rates of biochemically disease-free outcomes in prostate cancer.

SLCO2B1 Gene Polymorphisms Associated with Prostate Cancer Progression, Survival Following ADT

SLCO2B1 Gene Polymorphisms Associated with Prostate Cancer Progression, Survival Following ADT

By

Variants of gene SLCO2B1 associated with progression and survival among patients undergoing androgen deprivation therapy (ADT) for prostate cancer.

Cabozantinib Shows Promise Against Visceral Metastases

Cabozantinib Shows Promise Against Visceral Metastases

By

Compared with prednisone, cabozantinib does not improve overall survival rates for men with metastatic castration-resistant prostate cancer (mCRPC).

Docetaxel Does Not Improve Survival Following ADT for Hormone-Naïve Metastatic Prostate Cancer

Docetaxel Does Not Improve Survival Following ADT for Hormone-Naïve Metastatic Prostate Cancer

By

Adding docetaxel to androgen deprivation therapy (ADT) does not improve overall survival in hormone-naïve metastatic prostate cancer.

Prostate Tumor Androgen Receptor Abnormality Not Associated with Taxane Resistance

Prostate Tumor Androgen Receptor Abnormality Not Associated with Taxane Resistance

By

Androgen receptor V7 (AR-V7) status does not predict response to taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).

Bicalutamide Improves Survival in Advanced Nonmetastatic Hormone-Naïve Prostate Cancer

Bicalutamide Improves Survival in Advanced Nonmetastatic Hormone-Naïve Prostate Cancer

By

Adding bicalutamide improves overall survival among patients with advanced nonmetastatic hormone-naïve prostate cancer.

4Kscore Might Reduce Unnecessary Prostate Biopsies

4Kscore Might Reduce Unnecessary Prostate Biopsies

By

The 4Kscore could dramatically reduce the number of unnecessary prostate biopsies.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs